We are live on ! Find out more
QTTB icon

Q32 Bio

87 hedge funds and large institutions have $49.9M invested in Q32 Bio in 2022 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 20 increasing their positions, 28 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0.4% less ownership

Funds ownership: 2.85%2.45% (-0.4%)

18% less funds holding

Funds holding: 10687 (-19)

29% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 28

44% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 34

44% less capital invested

Capital invested by funds: $89.6M → $49.9M (-$39.7M)

97% less call options, than puts

Call options by funds: $36K | Put options by funds: $1.1M

Holders
87
Holders Change
-19
Holders Change %
-17.92%
% of All Funds
1.47%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
19
Increased
20
Reduced
28
Closed
34
Calls
$36K
Puts
$1.1M
Net Calls
-$1.07M
Net Calls Change
+$2.25M

QTTB Hedge Fund Activity: Q2 2022 in Review

87 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Q32 Bio (QTTB) for Q2 2022, worth a combined $49.9M — down 44% from $89.6M a quarter earlier.

Sellers outnumbered buyers: 34 funds closed out of QTTB and 19 opened new positions — a net loss of 15 holders — while 28 trimmed existing stakes and 20 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $1.37M. The largest seller was BlackRock, cutting an estimated $4.2M.

  • 87 institutional investors held Q32 Bio (QTTB) as of Q2 2022, down from 106 in Q1 2022.
  • Funds reported $49.9M of Q32 Bio stock for Q2 2022, down 44% quarter-over-quarter.
  • 19 funds opened new Q32 Bio positions in Q2 2022 and 34 closed out, a net change of -15 holders.
  • The largest Q32 Bio buyer in Q2 2022 was Millennium Management, an estimated $1.37M added.
  • The largest Q32 Bio seller in Q2 2022 was BlackRock, an estimated $4.2M sold.

Based on aggregated 13F filings for Q2 2022.